NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $515,000 | +56.5% | 28,689 | +49.4% | 0.01% | +40.0% |
| Q2 2021 | $329,000 | -15.4% | 19,198 | -1.2% | 0.01% | -28.6% |
| Q1 2021 | $389,000 | +15.1% | 19,429 | -2.4% | 0.01% | +16.7% |
| Q4 2020 | $338,000 | -52.7% | 19,904 | -53.8% | 0.01% | -60.0% |
| Q3 2020 | $715,000 | -44.5% | 43,079 | -27.9% | 0.02% | -74.1% |
| Q4 2019 | $1,289,000 | +119.2% | 59,737 | +85.1% | 0.06% | +346.2% |
| Q3 2019 | $588,000 | -25.3% | 32,268 | +46.0% | 0.01% | -31.6% |
| Q2 2019 | $787,000 | +51.1% | 22,107 | +42.7% | 0.02% | +35.7% |
| Q1 2019 | $521,000 | -41.1% | 15,494 | -42.4% | 0.01% | -54.8% |
| Q4 2018 | $884,000 | -37.9% | 26,891 | +15.2% | 0.03% | -42.6% |
| Q3 2018 | $1,424,000 | +294.5% | 23,352 | +215.9% | 0.05% | +237.5% |
| Q2 2018 | $361,000 | -44.8% | 7,393 | +20.2% | 0.02% | -55.6% |
| Q1 2018 | $654,000 | – | 6,153 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |